galactic plus bpc 157 MK677 + BPC157 Bundle BPC-157 Research Peptide | BPC-157

Flank or love-handle area

[2] Chang, C.H., et al

dorzolamide, brinzolamide) Local administration of felypressin in dental anaesthesia NOTE The detection in an Athletes Sample at all times or In-Competition , as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent (except topical ophthalmic administration of a carbonic anhydrase inhibitor or local administration of felypressin in dental anaesthesia), will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent

BPC-157 is not currently on the WADA prohibited list

Low Starting Amount Amount per injection: 200 mcg 6 units (0.06 mL) on a U-100 insulin syringe Frequency: Once daily, under the skin (subcutaneous) Cycle length: 812 weeks Inject near the target site or in the abdomen